Lexaria Bioscience Corp. (“Lexaria”) began developing DehydraTECH™ technology in 2014 and has since strengthened and broadened the technology to an unprecedented degree. Lexaria is a global leader in enhancing the speed and efficiency of orally-delivered drugs.
Lexaria has also demonstrated early-stage effectiveness in improvements of delivery through human skin for the potential development of topically-administered products, including patches, cremes and lotions.
Lexaria’s technology is currently being evaluated for improved delivery characteristics of antiretroviral drugs in the global fight against Coronavirus.
Lexaria operates four different wholly-owned subsidiary companies to each focus on commercial opportunities in their respective industries: Nicotine; Pharmaceuticals; Hemp; and Other. Together, they are empowered with global exclusive licenses to utilize and sub-license DehydraTECH worldwide for the delivery of molecules within their respective industries.
Lexaria has conducted ground-breaking studies to open doors previously closed to disruptive new delivery technology, including the possibility of potent and fast acting ingestible products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking. And, because of the demonstrated improvements in delivery, DehydraTECH also opens the possibility of utilizing micro doses in accordance with evolving FDA policies related to reducing delivered quantities of substances like nicotine.
Lexaria has demonstrated in animal studies a propensity for the DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain-barrier, initiating additional new patent applications, and opening possibilities for improved delivery of certain central nervous system-targeted drugs useful against Alzheimer’s Parkinson’s, and more.
Lexaria produces industry-leading research to support its novel delivery methods. Lexaria’s business model depends on industry partners who license its technology for additional R&D and consumer product development.
None of this can happen without the talented and dedicated people who have supported Lexaria’s development and growth. Lexaria’s internal and consulting team includes industry leaders, research scientists, clinicians, analytical chemists, medical schools and universities, intellectual property experts and partnering company collaborators
Lexaria is fortunate to be the recipient of widely varying experience and knowledge from advisors who consult with the company from time to time. These experts contribute knowledge and experience on an as-needed basis in these roles that are less formal than managers or directors. Still, we benefit from their involvement and are grateful for their presence.